Teijin Pharma Limited

Other

Teijin Limited

Tomomi Kosugi

Kenichiro Kataoka

Gen Unoki

Hiroaki Makino

Mika Takakuwa

Yuko Yamakoshi

Minoru Imai

Joelle Le

Tomio Takeuchi

Masa Hamada

Satoshi Sugiura

Masanori Yamamoto

Yoshiyuki Matsumoto

Takaharu Tsutsumi

Dale Mitchell

Kazuo Kitai

Yuri Sakai

Hiroshi Imai

Yasuhiro Oue

Akiko Takeuchi

Yoshinori Sugimoto

Kunihito Watanabe

Toshihiro Ishii

Donald James Simpson

Akira Nakano

Takahiro Takeuchi

Naotaka Suzuki

Tomohide Ida

Yoshimitsu Naniwa

Emiko Muratani

Robert Dale Mitchell

James Donald Simpson

Takami Tomiyama

John Clifford Harris

Clifford John Harris

Yohei Matsueda

Motoko Hamada

Aiko Fujino

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. 

Pyrazolo[1,5-a]pyrimidine derivatives

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. 

Pyrazolo[1,5-A] pyrimidine derivatives

The invention provides pyrrolo[3,2-d]pyrimidine derivatives represented by formula (I), and their medically acceptable salts. The compounds of the invention exhibit GSK-3 inhibiting activity and are therefore expected to be useful as therapeutic or prophylactic agents for conditions in which GSK-3 is implicated, such as diabetes, diabetes complications, Alzheimer's disease, neurodegenerative diseases, manic depression, traumatic encephalopathy, alopecia, inflammatory diseases, cancer and immune deficiency. 

Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors

A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth. 

Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof

A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor. 

Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof

Benzofurylpyrone derivatives

Growing community of inventors

Hino, Japan

Tomomi Kosugi